6 days ago
Fate of 23andMe genetic data still not settled amid bankruptcy fight
The fate of genetic data belonging to millions of 23andMe customers is again up in the air, as the bankrupt company seeks a judge's permission to consider another bid from its co-founder and undisclosed financial backers after previously accepting an offer from Regeneron Pharmaceuticals.
A nonprofit research institute backed by Anne Wojcicki, 23andMe's co-founder and former CEO, has been pressing 23andMe to consider additional bids purportedly topping Regeneron's $256 million cash offer last month, arguing that the bankruptcy auction was closed prematurely. That has put 23andMe in a bind, with the firm saying in court filings it was it risk of litigation unless it effectively reopened the auction to entertain final offers from Wojcicki's group and Regeneron.
